---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178092"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:20:11.149778+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio prices $175M equity financing; net proceeds ~$167M

## Summary
- Underwritten offering: 5.6M shares + 1.04M pre-funded warrants at $19.60/unit; net ~$122M.
- Gilead purchases 2.3M shares + warrants in private placement at same price; net ~$45M.
- Class A warrants exercisable at $21.60, expire 5 years from issuance or 30 days after Phase 2 enrollment announcement.
- Class B warrants exercisable after Nov 15, 2026 until Dec 31, 2026; terminate early if $75M non-dilutive collaboration capital received.
- Proceeds for general corporate purposes; closings on August 11, 2025.

## SEC filing metadata
- accession: 0001193125-25-178092
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312525178092/0001193125-25-178092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312525178092/d442009d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178092
- JSON: https://secwatch.observer/filing/0001193125-25-178092.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.